Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease

Por Guo, Shuling, Booten, Sheri L, Watt, Andrew, Alvarado, Luis, Freier, Susan M, Teckman, Jeffery H, McCaleb, Michael L, Monia, Brett P
Publicado em 2014

Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin–related liver disease in mice

Por Guo, Shuling, Booten, Sheri L., Aghajan, Mariam, Hung, Gene, Zhao, Chenguang, Blomenkamp, Keith, Gattis, Danielle, Watt, Andrew, Freier, Susan M., Teckman, Jeffery H., McCaleb, Michael L., Monia, Brett P.
Publicado em 2013

Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice

Por Nuñez‐Durán, Esther, Aghajan, Mariam, Amrutkar, Manoj, Sütt, Silva, Cansby, Emmelie, Booten, Sheri L., Watt, Andrew, Ståhlman, Marcus, Stefan, Norbert, Häring, Hans‐Ulrich, Staiger, Harald, Borén, Jan, Marschall, Hanns‐Ulrich, Mahlapuu, Margit
Publicado no Hepatol Commun (2017)

Inhibition of Protein Tyrosine Phosphatase-1B with Antisense Oligonucleotides Improves Insulin Sensitivity and Increases Adiponectin Concentrations in Monkeys

Por Swarbrick, Michael M., Havel, Peter J., Levin, Arthur A., Bremer, Andrew A., Stanhope, Kimber L., Butler, Madeline, Booten, Sheri L., Graham, James L., McKay, Robert A., Murray, Susan F., Watts, Lynnetta M., Monia, Brett P., Bhanot, Sanjay
Publicado em 2009

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice

Por Prakash, Thazha P., Graham, Mark J., Yu, Jinghua, Carty, Rick, Low, Audrey, Chappell, Alfred, Schmidt, Karsten, Zhao, Chenguang, Aghajan, Mariam, Murray, Heather F., Riney, Stan, Booten, Sheri L., Murray, Susan F., Gaus, Hans, Crosby, Jeff, Lima, Walt F., Guo, Shuling, Monia, Brett P., Swayze, Eric E., Seth, Punit P.
Publicado em 2014